Risperdal, Zyprexa “approvable’ for teen schizophrenia
Executive Summary
FDA issues an "approvable" letter June 21 to Johnson & Johnson unit Janssen for Risperdal (risperidone) to treat schizophrenia in children ages 13-17. A potential competitor in the space, Lilly's Zyprexa (olanzapine), is also approvable for an identical indication. Lilly told "The Pink Sheet" it received an approvable letter April 30 for Zyprexa to treat teen schizophrenia and acute mania associated with bipolar I disorder in children ages 10-17 years. FDA did not request any new clinical trials for either drug, according to the firms. The sNDAs for both drugs received "priority" review...
You may also be interested in...
Lilly Zyprexa (correction)
Lilly received an "approvable" letter from FDA on April 30 for its submission of two sNDAs for Zyprexa (olanzapine) for the treatment of schizophrenia and acute mixed or manic episodes associated with bipolar I disorder in adolescents, ages 13 to 17. A recent article in "The Pink Sheet" misstates the ages for proposed pediatric indications (1"The Pink Sheet" June 25, 2007, In Brief)...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.